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OBJECTIVES—Acute liver failure (ALF) is classically defined by coagulopathy and hepatic
encephalopathy (HE); however, acute liver injury (ALI), i.e., severe acute hepatocyte necrosis
without HE, has not been carefully defined nor studied. Our aim is to describe the clinical course
of specifically defined ALI, including the risk and clinical predictors of poor outcomes, namely
progression to ALF, the need for liver transplantation (LT) and death.
METHODS—386 subjects prospectively enrolled in the Acute Liver Failure Study Group registry
between 1 September 2008 through 25 October 2013, met criteria for ALI: International
Normalized Ratio (INR)≥2.0 and alanine aminotransferase (ALT)≥10× elevated (irrespective of
bilirubin level) for acetaminophen (N-acetyl-p-aminophenol, APAP) ALI, or INR≥2.0, ALT≥10×
elevated, and bilirubin≥3.0 mg/dl for non-APAP ALI, both groups without any discernible HE.
Subjects who progressed to poor outcomes (ALF, death, LT) were compared, by univariate
analysis, with those who recovered. A model to predict poor outcome was developed using the
random forest (RF) procedure.

Author Manuscript

RESULTS—Progression to a poor outcome occurred in 90/386 (23%), primarily in non-APAP
(71/179, 40%) vs. only 14/194 (7.2%) in APAP patients comprising 52% of all cases (13 cases did
not have an etiology assigned; 5 of whom had a poor outcome). Of 82 variables entered into the
RF procedure: etiology, bilirubin, INR, APAP level and duration of jaundice were the most
predictive of progression to ALF, LT, or death.
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CONCLUSIONS—A majority of ALI cases are due to APAP, 93% of whom will improve rapidly
and fully recover, while non-APAP patients have a far greater risk of poor outcome and should be
targeted for early referral to a liver transplant center.

INTRODUCTION

Author Manuscript

Patients who develop severe acute liver injury (ALI) without preexisting chronic liver
disease, oft en demonstrate significant liver dysfunction marked by coagulopathy (defined as
an International normalized ratio (INR)≥1.5), and are classically designated as acute liver
failure (ALF) when any degree of hepatic encephalopathy (HE) is present (1–3). However,
little is known about the earlier stages of ALI where there may be significant coagulopathy,
but no discernible HE (4). We explored this apparently milder stage of liver injury, its causes
and the relative risk of poor outcomes, namely, progressing to ALF, receiving a liver
transplant (LT) or dying within 3 weeks from admission to the study. To describe the clinical
features and natural history of ALI, and to identify patients most at risk for poor outcomes,
we proposed a new strictly defined category of ALI, specifically to capture additional
information about subjects with severe liver injury without HE. Beginning in 2008, we
adopted the same multicenter registry design, study sites and forms for enrolling patients
with ALF by our Acute Liver Failure Study Group (ALFSG) to prospectively collect data
from ALI patients in parallel to the data already being collected from classic ALF patients.
The current report describes this newly defined ALI cohort. Using these data, we applied
random forest (RF), to identify those with ALI at risk of progression to ALF and other poor
outcomes.

METHODS
Author Manuscript

Study population
We prospectively studied 386 consecutive subjects who were considered to have ALI and
who were enrolled into the NIH-funded ALFSG registry from 1 September 2008 through 25
October 2013. After an ALFSG workshop to define ALI in the ALFSG registry, criteria
were agreed upon and enrollment of subjects with ALI began in September 2008, from up to
23 academic centers in the United States. ALI was defined as follows: absence of HE and,
either:
Acetaminophen (n-acetyl-p-aminophenol, APAP) ALI:
INR≥2.0 and ALT≥10×upper limit of normal
Or

Author Manuscript

Non-acetaminophen (non-APAP) ALI:
INR≥2.0, ALT≥10×upper limit of normal, and bilirubin≥3.0 mg/dl
According to the study protocol, patients were eligible if the peak INR was>2.0 within 48 h
of enrollment. Only patients without pre-existing chronic liver disease were eligible for
enrollment. Etiology was determined by each study center’s principal investigator, based on
historical, clinical, laboratory, and radiographic data, as well as liver histopathologic results,
when available. Diagnoses of etiology (APAP/non-APAP) were established using standard
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criteria: for APAP, a history of any acetaminophen ingestion and/or parent compound
(acetaminophen blood level) positive, plus alanine aminotransferase “ALT”, or aspartate
aminotransferase (AST) levels≥1,000 IU/l with bilirubin<10 mg/dl; for non-APAP, patients
in whom acetaminophen toxicity could be reasonably excluded. If an extensive search for
the cause of ALI was inconclusive, the etiology was recorded as Indeterminate. HE, defined
as the presence of disorientation or asterixis, was assessed by the study site principal
investigator at the time of enrollment and on each subsequent day that the subject was
enrolled in the registry. If present, HE severity was classified according to the West-Haven
criteria (5).
Data management and integrity

Author Manuscript

Written informed consent was obtained from the enrolled subjects, as they were not
encephalopathic. Patient demographics, medical history, clinical features, and laboratory
values were collected prospectively at study enrollment, and clinical status and laboratory
results were also recorded serially for up to 7 days, or until discharge, death, or transplant if
prior to 7 days. All data are managed and housed on a central server by the ALFSG
Statistical and Data Management Center at the Medical University of South Carolina. Each
center’s Institutional Review Board approved the study.
Statistical Analyses

Author Manuscript

Data from the 386 subjects on the day of enrollment into the study were used for the
analyses and included the following: subject demographics (age, gender, and race), calendar
year of enrollment and center where enrollment occurred, dates of first symptom, and onset
of jaundice and encephalopathy, etiology of the acute illness, use of N-acetylcysteine (NAC),
blood product transfusion, measures of systemic distress (blood pressure, heart rate,
temperature, pH, serum lactate levels, and need for vasopressor support, mechanical
ventilation, or renal replacement therapy), and laboratory data, including measures of liver
injury and dysfunction (serum bilirubin, aminotransferases, albumin, and INR). Descriptive
statistics were performed and results expressed as medians (and interquartile ranges) and n
(%) for continuous and categorical variables, respectively. Wilcoxon rank sum and χ2 tests
were used as appropriate, and subjects with missing data were not included in the univariate
analyses of the variables for which data were missing. Our primary outcome was the
composite occurrence within 21 days of enrollment of either progression to ALF, receiving a
LT, or dying. In some instances, ALI alone led to liver transplantation or death without an
apparent phase of ALF. Associations with a P<0.05 were considered statistically significant.
Univariate analyses were performed using SAS (v 9.1.03 Cary, NC).

Author Manuscript

A model to predict poor outcome, i.e., ALF, LT, or death, was developed using the RF
procedure first developed by Breiman in 2001 (6). The resulting model was then applied to
the validation dataset of 163 subjects enrolled from November 2013 to September 2015. RF
is a statistical method that iteratively develops decision trees, or models, using binary splits
on predictor variables, thus providing a mechanism for estimating the probability that each
individual ALI patient will have a poor outcome. In addition, the RF procedure provides
information about which input variables are most important for the prediction of poor
outcome, referred to as importance measures(7). The procedure is an alternative approach to
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more common prediction models such as logistic regression and can be used to overcome
the statistical obstacles of correlated predictors, non-normality of predictor variables and
missing data(6,8,9). The method has been used previously to determine etiology in the ALF
population using the ALFSG registry(9). RF modeling was performed using R soft ware
version 2.15.1(8). See the Supplementary Material online for a detailed description of the
RF procedure.

RESULTS
Patient demographics

Author Manuscript

All 386 subjects with defined ALI enrolled in the ALFSG registry during the initial study
period were included in the analysis. Of these 386 subjects, several had an INR<2.0 at the
time of enrollment into the study. However, they were eligible for entry into the registry
since their peak INR was>2.0 within 48 h of enrollment. The majority were women (61%)
and Caucasian (72%) with a median age of 38.0 (interquartile range 28.0–49.0) years (Table
1). APAP toxicity was the most common cause of ALI, accounting for 194 (50%) cases,
followed by 46 (12%) due to autoimmune hepatitis, and 42 (11%) considered as
Indeterminate cases. There were 13 subjects who had not received an etiologic diagnosis at
the time of the data analysis. On average, subjects had marked elevations of
aminotransferase levels, with median AST 2,270 U/l (929–5,219 U/l) and ALT 2,784 U/l
(942–5,713 U/l). Serum bilirubin (5.1 mg/dl, 2.6–15.6 mg/dl) and INR (2.4, 2.1–3.4) were
moderately elevated as was venous ammonia (65.5 µmol/dl, 41.0–94.0 µmol/dl). Subjects
developed symptoms on average 5 days prior (2.0–14.0 days) and the onset of jaundice on
average 4 days prior (1.0–10.0 days), to enrolling in the study. The most common symptoms
reported include nausea and vomiting (290/383, 76%), abdominal pain (272/383, 71%), joint
pain (55/383, 14%), and peripheral edema (37/367, 10%). Kidney injury requiring renal
replacement therapy was rare, occurring in only 8 subjects (2%). Overall, 68% of the
subjects were treated with NAC at some time during hospitalization. The majority (90%) of
APAP cases received NAC compared to 30% of the non-APAP cases. Forty-three subjects
(11%) were transfused blood products, particularly fresh frozen plasma (FFP) that accounted
for 88% of the transfusions.

Author Manuscript
Author Manuscript

Comparing APAP to the other ALI etiologies, there was no gender difference, but APAP
ALI subjects were younger, 34.5 years (27 years—46 years) vs. 44 years (33 years—55
years, P<0.001) and more frequently Caucasian than the non-APAP subjects (79 vs. 64%,
P<0.001, Table 2). Aminotransferase levels were nearly 4-fold higher in APAP compared to
non-APAP ALI subjects, but both bilirubin (3.2 mg/dl, 1.9–4.6 mg/dl vs. 15.7 mg/dl, 8.1–
23.4 mg/dl, P<0.001) and phosphate (2.2 mmol/l, 1.6–3.0 mmol/l vs. 3.3 mmol/l, 2.7–4.2
mmol/l, P<0.001) were lower. Subjects with APAP toxicity also had a shorter duration of
symptoms (3 days, 2.0–4.0 days vs. 11 days, 6.0–24.0 days, P<0.001) and jaundice (1 day,
1.0–2.0 days vs. 8 days, 3.0–16.0 days, P<0.001) prior to enrollment.
Outcomes
During the study period, 90/386 (23%) subjects developed one or more of the three primary
outcomes, not all of which involved ALF (Table 3). Of these, 72/386 (19%) subjects
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progressed to ALF, 19/386 (5%) subjects died and 44/386 (11%) underwent LT. NonCaucasians had a greater risk of poor outcome than whites (31 vs. 20%, P=0.026) as did
older subjects, but there was no difference between men and women (Table 3). Those with
disease progression also had a more protracted clinical course with a longer duration of
symptoms (11 days vs. 4 days, P<0.001) and jaundice (8 days vs. 3 days, P<0.001) before
admission to the study. Those who were destined for a poor outcome were significantly
more likely to have non-APAP liver injury (40% non-APAP vs. 7.2% APAP, P<0.001). The
worse outcomes for non-APAP ALI was primarily due to their greater risk of developing
ALF (56/179, 31% non-APAP cases developed ALF compared to 11/194, 6% of APAP
cases, P<0.001). Accordingly, bilirubin (17.5 mg/dl vs. 4.0 mg/dl, P<0.001), INR (2.8 vs.
2.3, P<0.001), and lactate (3.0 mmol/l, vs. 2.0 mmol/l, P<0.001) levels were higher in
subjects with poor outcomes, but aminotransferase levels were lower (ALT: 1,165.0 U/l vs.
3,330.0 U/l, P<0.001; and AST: 1,450.0 U/l vs. 2,642.0 U/l, P<0.001). Subjects who
progressed to ALF, death or LT were also more likely to be transfused blood products than
those in whom ALI resolved (27 vs. 8%, respectively, P<0.001). Finally, 261 (68%) of
subjects were treated with NAC during the study period; the majority (81%) were APAP
cases. Overall, fewer patients treated with NAC progressed to ALF, died or underwent LT
compared to subjects who did not receive NAC (19 vs. 32%, P=0.005); however, this was
primarily driven by the large number of APAP cases nearly all of whom were given NAC,
and their very low overall risk of doing poorly. For the non-APAP cases, there was no
association between NAC use and outcome (Table 3).

Author Manuscript

Overall, 19/386 (5%) subjects died and 45/386 (12%) underwent LT. Of the subjects who
died, 10/19 (53%) had progressed to ALF (Table 3) including one who underwent LT, dying
postoperatively. Additionally, not all patients who died appeared to progress to ALF (Table
4). Although the small number of deaths precludes detailed analysis, it did not appear that a
specific ALI etiology was over-represented among the deaths. The deaths recorded were as
follows: APAP toxicity (4), indeterminate (4), autoimmune hepatitis (5), hepatitis B (3),
ischemia (2), and DILI (1). The commonest causes of death mentioned were multisystem
organ failure (4) and progressive liver failure (4). The number of patients (by etiology) who
underwent liver transplantation included APAP toxicity (3), autoimmune hepatitis (15), DILI
(2), hepatitis A (2), hepatitis B (3), mushroom intoxication (2), Wilson disease (2), and
indeterminate (13). Two transplant patients had missing etiologies.
Modeling the risk of having a poor outcome

Author Manuscript

A RF model was created to determine the risk for the primary composite outcome to occur,
namely progressing to ALF, having a LT, or dying within 21 days of enrolling into the study
(see the Supplementary Material for a detailed description of the RF procedure). Eighty-two
variables were considered based on results from the univariate analyses. For calculations
used in model building, non-APAP cases were assigned an APAP blood level of zero. To
simplify the model without compromising predictability, a variable selection procedure
identified the most predictive variables for inclusion in the final model: etiology, admission
values of bilirubin, INR, acetaminophen level, and duration of jaundice prior to enrollment.
The most important variable for determining risk of poor outcome was etiology, followed in
order by the reported duration from onset of jaundice to study admission, acetaminophen
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level, bilirubin, and INR. The final model yielded an overall prediction accuracy of 81% and
an area under the receiver operating curve of 0.84, indicating overall good model
performance. Correct predictions were made for 83% (245/296) of ALI patients who had
resolution of their underlying liver injury and for 76% (68/90) of the ALI patients who did
progress to ALF, received LT, or died.
The RF model was applied to the validation cohort of 163 ALI subjects. There were no
clinical differences between the training and validation datasets (Supplementary Table 1).
Overall accuracy for the validation dataset was 75%, with accurate predictions for 67%
(95/141) of ALI patients who did not progress to ALF, death or LT and 88% (28/32) of ALI
patients who did progress to ALF, death or LT. Thus, the model generally made conservative
predictions.

Author Manuscript

Partial dependence plots allowed for analysis of the relationship between outcome and
variables included in the RF model (data not shown). Etiologies more associated with a
higher chance of poor outcomes than other causes were pregnancy-associated liver injury,
autoimmune hepatitis, infection with hepatitis A or B, mushroom intoxication, Wilson
disease, Indeterminate diagnoses, and other viruses. Aside from etiology, thresholds that
were derived from the remaining variables and that identified the at risk subjects included
jaundice for greater than 3 days, bilirubin level greater than 3 mg/dl, APAP level greater than
60 mg/l or INR greater than 1.7.

DISCUSSION

Author Manuscript
Author Manuscript

The original definition of ALF, sometimes termed fulminant hepatic failure, derived from a
review article in 1970 by Trey and Davidson (1), included the presence of HE and
coagulopathy in patients without pre-existing liver disease. While HE is a useful clinical
marker (10), it is also a subjective one. Our knowledge of severe liver injury has been
derived primarily from patients with HE, whereas, to-date, there have only been a few
studies of the outcome of severe liver injury that falls short of ALF (11–18). The current
study satisfies that unmet need. Therefore, in an effort to further understand and expand the
repertoire of patients with severe hepatocyte necrosis and its sequelae, we developed criteria
for ALI without HE to include patients with advanced disease by using a higher INR
threshold (>2.0), eliminating to some extent those who might have a milder, non-progressive
condition. We intended to provide some unique insights into the causes and natural
progression of a cohort of ALI patients in whom HE had not yet occurred, to better
determine what might trigger progression to ALF, need for LT, or death within 21 days of
study enrollment. This analysis could aid clinicians’ assessment and management of patients
with severe liver injury who lack the crucial feature of HE.
As with ALF, the majority of ALI cases occurred in Caucasian women and was due to APAP
toxicity. This contrasts with the 25% APAP prevalence reported recently from King’s
College Hospital (KCH) in London UK, in a more severe version of ALI than defined here,
as the KCH cases included both HE and non-HE patients who required Intensive Care Unit
admission(19). Among the ALI etiologies, APAP toxicity stands out as being considered
‘hyperacute(20),’ characterized by very short duration of symptoms (<3 days), marked
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elevation of aminotransferases and only mildly abnormal bilirubin levels. Despite the
severity of laboratory abnormalities, these cases appear self-limited, as recovery of ALI due
to APAP toxicity is nearly universal—here only 7% progressed to ALF, died, or needed LT.
Conversely, non-APAP ALI patients tend to have a longer duration of symptoms and
jaundice with more marked elevation of bilirubin and worse overall outcomes. Accordingly,
the probability of progressing to ALF is greater with autoimmune hepatitis, DILI, and
indeterminate etiologies, accounting for 61% of the cases. Additionally, treating non-APAP
ALI patients with NAC did not appear to reduce the risk of developing ALF in our
population. Death was also not confined to those ALI patients who progressed to ALF since
half of the patients who died did not appear to pass through that stage as shown in Table 3;
many were listed as dying of multi-organ failure or central nervous system or other
conditions that were specific and not necessarily associated with encephalopathy. However,
it is possible that case report form data did not reflect the exact details of disease
progression, and some of these cases may have actually developed ALF. Notwithstanding,
transfer to a liver transplant center is important in all forms of ALI, but particularly so for
non-APAP cases (of whom 40% had with poor outcomes, compared to only 7.2% of APAP
subjects), to permit early evaluation for liver transplantation.

Author Manuscript

Using a novel, multivariable RF modeling system, we identified clinical variables associated
with progression to ALF, need for LT, or death and created a tool to estimate this probability
of disease progression to a poor outcome. We opted for this statistical analysis rather than
the more conventional logistic regression modeling since RF is able to account for missing
data and is not affected adversely by interactions in the data. The result was a model that
provides an estimate for the probability of poor outcome with an accuracy of 81%. Several
variables were examined: the most influential within the RF model were ALI etiology,
duration of symptoms, and study admission blood levels of bilirubin, APAP (which is zero
in non-APAP cases), and INR. Each of these should be readily available to clinicians,
allowing for estimation of the risk in any hospital setting. Although the overall accuracy of
the model in the validation set was lower than in the model creation set, the model actually
performed better for those subjects with a poor outcome compared to those who recovered.
An added benefit of RF analysis is the ability to dichotomize the predictive variables into
thresholds that predict the outcome, allowing for quick assessment at the bedside. These
include jaundice for greater than 3 days, bilirubin greater than 3 mg/dl, acetaminophen level
greater than 60 mg/l, and INR greater than 1.7 (See Supplementary Material).

Author Manuscript

Of interest is the potential risk that transfusion of blood products, particularly FFP, appeared
to have for patients with ALI. Although having a transfusion was not determined to be a
predictive variable for disease progression for any of the three outcomes outlined in the RF
model, 42% of the subjects who received FFP had a poor outcome as compared to 58% of
those who did not. The clinical justification for transfusion in each subject was not available.
The association between FFP use and progression to ALF or other outcomes does not
necessarily indicate that FFP is contributing to worse liver injury since it may be that the
presence of worse liver disease prompted the clinician to use FFP. However, there is
evidence that ALF is a hypercoagulable state and it is possible that administration of clotting
factors enhanced intrahepatic thrombosis that contributed to impairment in liver function
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(21,22). Further studies would be needed to determine if there is inherent risk with
transfusion in these subjects, but prudence should be exercised with regard to transfusion,
especially given the growing awareness that the standard hematologic and coagulation
indices (such as the INR and platelet count) do not necessarily predict bleeding risk either in
patients with acute (21,23–26) or chronic (23,27,28) liver diseases.

CONCLUSION

Author Manuscript

In this in-depth analysis of the natural history of ALI, according to the specific criteria we
defined, the likelihood and risk factors for poor outcome directly or indirectly related to liver
disease were determined. APAP toxicity (52%) was the most common cause of ALI, while
non-APAP causes were observed to have a greater risk of poor outcome, particularly when
compared to APAP-induced liver injury. Patients at risk of a poor prognosis were identified
with 81% accuracy using a multivariable RF predictive model.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓

Patients with acute liver failure have coagulopathy and encephalopathy.

✓

Acute liver failure is associated with high mortality.

WHAT IS NEW HERE

Author Manuscript

✓

A detailed natural history study of patients with less severe acute liver injury
prior to developing encephalopthy.

✓

Patients with acute liver injury at risk for a poor outcome can be identified
using our prognostic score.

✓

Death in patients with acute liver injury can occur even without progression
to acute liver failure.

Author Manuscript
Author Manuscript
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Table 1

Author Manuscript

Clinical variables of enrolled subjects with acute liver injury
Admission variables

Overall population (N=386)

Age (years)

38.0 (28.0–49.0)

Gender
Male

151 (39%)

Female

235 (61%)

Race
Caucasian

276 (72%)

African American

70 (18%)

Other

40 (10%)

Etiology of ALIa

Author Manuscript

APAP toxicity

194 (50%)

Autoimmune hepatitis

46 (12%)

Indeterminate

42 (11%)

Hepatitis A

25 (6%)

Drug-induced liver injury

23 (6%)

Ischemia

12 (3%)

Other

31 (8%)

Duration of symptoms (days)

5.0 (2.0–14.0)

Duration of jaundice (days)

4.0 (1.0–10.0)

Bilirubin (mg/dl)

5.1 (2.6–15.6)

Creatinine (mg/dl)

0.9 (0.6–1.4)

Author Manuscript

AST (U/l)

2,269.5 (929.0–5,219.0)

ALT (U/l)

2,784.0 (942.0–5,713.0)

Alkaline Phosphatase (IU/ml)

117.0 (87.0–161.5)

Albumin (mg/dl)

2.9 (2.5–3.2)

INR

2.4 (2.1–3.4)

Phosphate (mmol/l)

2.7 (1.9–3.6)

Venous ammonia (µmol/dl)

65.5 (41.0–94.0)

ALI, acute liver injury; ALT, alanine aminotransferase; APAP, N-acetyl-p-amino-phenol; AST, aspartate aminotransferase; INR, International
normalized ratio.

a

Etiology not recorded for 13 subjects.

Author Manuscript
Am J Gastroenterol. Author manuscript; available in PMC 2017 September 06.

Koch et al.

Page 13

Table 2

Author Manuscript

Clinical variables according to ALI etiologya
Admission variables

APAP
ALI (N=194)

Non-APAP
ALI (N=179)

P valueb

Age (years)

34.5 (27–46)

44 (33–55)

<0.001

Gender

0.14

Male

69 (36%)

77 (43%)

Female

125 (64%)

102 (57%)

Race

<0.001

Caucasian

154 (79%)

114 (64%)

African American

31 (16%)

38 (21%)

9 (5%)

27 (15%)

Duration of symptoms (days)

3.0 (2.0–4.0)

11.0 (6.0–24.0)

<0.001

Duration of jaundice (days)

1.0 (1.0–2.0)

8.0 (3.0–16.0)

<0.001

Bilirubin (mg/dl)c

3.2 (1.9–4.6)

15.7 (8.1–23.4)

<0.001

Creatinine (mg/dl)

0.9 (0.7–1.7)

0.9 (0.6–1.3)

0.20

AST (U/l)

4,506.0 (2,110.0–8,048.0)

1,331.0 (561.0–2,293.0)

<0.001

ALT (U/l)

4,837.0 (2,489.0–7,880.0)

1,135.0 (653.0–2,813.0)

<0.001

98.0 (74.0–124.0)

143.0 (110.0–193.0)

<0.001

Albumin (mg/dl)

3.1 (2.7–3.3)

2.6 (2.2–2.9)

<0.001

INR

2.6 (2.1–4.0)

2.3 (2.2–2.9)

0.03

Phosphate (mmol/l)

2.2 (1.6–3.0)

3.3 (2.7–4.2)

<0.001

68.0 (42.0–96.0)

63.0 (41.0–83.0)

0.54

Other

Author Manuscript

Alkaline phosphatase (IU/ml)

Venous ammonia (µmol/dl)
Primary outcome

<0.001

Author Manuscript

Progressed to ALF only

7 (4%)

16 (9%)

Transplant only

0 (0%)

10 (6%)

Death only

3 (2%)

7 (4%)

More than one of the above

4 (2%)

40 (22%)

180 (93%)

106 (59%)

Alive/no transplant/no progression to ALF

ALI, acute liver injury; ALF, acute liver failure; ALT, alanine aminotransferase; APAP, N-acetyl-p-aminophenol; AST, aspartate aminotransferase;
INR, International normalized ratio.

a

Etiology not recorded for 13 subjects.

b

Univariate Comparisons between APAP ALI and non-APAP ALI.

c

The definition of APAP ALI included any bilirubin level, whereas for non-APAP ALI, bilirubin>3 mg/dl was the threshold for inclusion.
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Table 3

Author Manuscript

Clinical measures and ALI outcome
N

Liver recovered (N=296)

Poor outcomea (N=90)

P value

Age (years)

386

37.0 (28.0–48.0)

44.5 (32.0–56.0)

0.002

Gender

386

Male
Female

Race

0.30
120 (41%)

31 (34%)

176 (59%)

59 (66%)

386

0.062

Caucasian

220 (74%)

56 (62%)

African American

50 (17%)

20 (22%)

26 (9%)

14 (16%)

Other

Etiology†

373

Author Manuscript

APAP

<0.001
180 (63%)

Non-APAP

14 (16%)

Author Manuscript

108 (37%)

71 (84%)

Duration of symptoms (days)

376

4.0 (2.0–9.0)

11.0 (5.0–21.0)

<0.001

Duration of jaundice (days)

230

3.0 (1.0–8.0)

8.0 (2.0–16.0)

<0.001

Bilirubin (mg/dl)

378

4.0 (2.2–9.5)

17.5 (8.2–24.4)

<0.001

AST (U/l)

382

2,642.0 (1,038.0–6,127.0)

1,450.0 (669.0–2,584.0)

<0.001

ALT (U/l)

382

3,330.0 (1,250.0–6,227.0)

1,165.0 (660.0–3,061.0)

<0.001

Alkaline Phosphatase (IU/ml)

380

112.0 (81.0–148.0)

139.0 (105.0–183.0)

<0.001

Albumin (mg/dl)

350

3.0 (2.6–3.3)

2.6 (2.3–2.9)

<0.001

INR

368

2.3 (2.0–3.1)

2.8 (2.2–4.4)

<0.001

Creatinine (mg/dl)

380

0.9 (0.6–1.4)

1.0 (0.7–1.3)

0.465

Phosphate (mmol/l)

310

2.5 (1.8–3.4)

3.1 (2.3–4.3)

<0.001

Venous ammonia (μmol/dl)

112

65.5 (41.0–88.)

65.0 (41.0–114.0)

0.591

Transfusion

386

No

273 (92%)

66 (73%)

Yes

23 (8%)

24 (27%)

386

16 (5%)

22 (24%)

<0.001

Overall

386

211 (71%)

50 (56%)

0.005

Non-APAP ALI

179

42 (39%)

33 (46%)

0.314

FFP transfusion

<0.001

NAC use

ALF, acute liver failure; ALI, acute liver injury; ALT, alanine aminotransferase; APAP, N-acetyl-p-aminophenol; AST, aspartate aminotransferase;
FFP, fresh frozen plasma; IQR, interquartile range; LT, liver transplantation.
Categorical data presented as n (%) and continuous data as median (IQR).
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†

Etiology not recorded for 13 subjects.

a

Poor outcome includes ALF and/or LT and/or death.
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Table 4

Author Manuscript

Characteristics of 19 ALI subjects who died within 21 days of enrollment
ALI etiology

Author Manuscript

Progression
to ALF

Time from
enrollment to
death (days)

Cause of death

1. APAP

No

2

Cardiac arrest

2. Hepatitis B

Yes

3

Multisystem organ Failure/sepsis

3. Shock/ischemia

Yes

11

Unknown

4. Autoimmune hepatitis

Yes

16

Unknown

5. DILI

Yes

8

Multisystem organ failure

6. APAP

Yes

8

Neurological (cerebral edema)

7. Indeterminate

No

1

Unknown

8. Indeterminate

Yes

11

Neurological (cerebral edema)

9. APAP

No

8

Pulmonary embolism

10. Autoimmune hepatitis

Yes

7

Liver failure

11. Indeterminate

Yes

4

Multisystem organ failure/sepsis

12. Autoimmune hepatitis

No

13

Multisystem organ Failure

13. Autoimmune hepatitis

Yes

4

PEA arrest

14. Shock/ischemia

No

14

Multisystem organ failure

15. APAP

No

10

Liver failure

16. Hepatitis B

No

9

Liver failure

17. Indeterminate

No

18

Unknown

18. Hepatitis B

No

20

Liver failure

19. Autoimmune hepatitisa

Yes

17

Intracardiac thrombosis

Author Manuscript

ALI, acute liver injury; ALF, acute liver failure; APAP, N-acetyl-p-aminophenol; DILI, drug-induced liver injury; PEA, pulseless electrical activity.

a

Patient died shortly after liver transplant.
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